{"id":"interferon-beta-1a-oral-doxycycline","safety":{"commonSideEffects":[{"rate":"40-60%","effect":"Flu-like symptoms (interferon)"},{"rate":"20-40%","effect":"Injection site reactions (interferon)"},{"rate":"10-20%","effect":"Gastrointestinal upset (doxycycline)"},{"rate":"5-10%","effect":"Photosensitivity (doxycycline)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Neutropenia"}]},"_chembl":{"chemblId":"CHEMBL1201562","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon beta-1a is a cytokine that activates natural killer cells and macrophages to enhance antiviral immunity and modulate immune responses in conditions like multiple sclerosis. Doxycycline is a tetracycline antibiotic with additional anti-inflammatory properties that inhibit matrix metalloproteinases and reduce inflammatory cytokine production. The combination leverages immunomodulation and anti-inflammatory mechanisms, though this particular pairing is unconventional and likely represents a research or investigational protocol rather than a standard marketed formulation.","oneSentence":"Interferon beta-1a enhances immune response against viral infections and autoimmune disease, while oral doxycycline provides broad-spectrum antibiotic and anti-inflammatory effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:49:19.617Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple sclerosis (interferon beta-1a component)"},{"name":"Investigational combination therapy (specific indication unclear)"}]},"trialDetails":[{"nctId":"NCT00246324","phase":"PHASE4","title":"Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis","status":"COMPLETED","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"2003-12","conditions":"Multiple Sclerosis","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avonex"],"phase":"marketed","status":"active","brandName":"Interferon beta 1a, oral doxycycline","genericName":"Interferon beta 1a, oral doxycycline","companyName":"Louisiana State University Health Sciences Center Shreveport","companyId":"louisiana-state-university-health-sciences-center-shreveport","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Interferon beta-1a enhances immune response against viral infections and autoimmune disease, while oral doxycycline provides broad-spectrum antimicrobial and anti-inflammatory effects. Used for Multiple sclerosis (interferon beta-1a component), Investigational combination therapy (specific indication unclear from available data).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}